CO VALACYCLOVIR TABLET

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE)

Доступно од:

COBALT PHARMACEUTICALS COMPANY

АТЦ код:

J05AB11

INN (Међународно име):

VALACICLOVIR

Дозирање:

1000MG

Фармацеутски облик:

TABLET

Састав:

VALACYCLOVIR (VALACYCLOVIR HYDROCHLORIDE) 1000MG

Пут администрације:

ORAL

Јединице у пакету:

21/30/100

Тип рецептора:

Prescription

Терапеутска област:

NUCLEOSIDES AND NUCLEOTIDES

Резиме производа:

Active ingredient group (AIG) number: 0128626003; AHFS:

Статус ауторизације:

CANCELLED PRE MARKET

Датум одобрења:

2017-09-01

Карактеристике производа

_ _
_ _
_Page 1 of 40_
PRODUCT MONOGRAPH
PR
_CO _VALACYCLOVIR
Valacyclovir Hydrochloride Tablets
500 mg and 1000 mg valacyclovir (as valacyclovir hydrochloride)
Antiviral Agent
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 6J5
Date of Revision:
February 01, 2016
Control No.: 191484
_ _
_ _
_Page 2 of 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 17
STORAGE AND STABILITY
.........................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 19
PART II: SCIENTIFIC INFORMATION
..............................................................................
20
PHARMACEUTICAL INFORMATION
.........................................................................
20
CLINICAL TRIALS
.........................................................................................................
21
DETAILED PHARMACOLOGY
...............